Dr. Pol Vandenbroucke describes the alarming global threat of antimicrobial resistance.
Segment Description: Dr. Pol Vandenbroucke, Chief Medical Officer for Pfizer’s hospital business unit, describes the alarming threat of antimicrobial resistance.
Related Coverage:
The AMR Action Fund, an initiative of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), an international body representing the R&D pharmaceutical industry, was announced at simultaneous virtual launch events in Berlin and Washington, DC.
“With the AMR Action Fund, the pharmaceutical industry is investing nearly $1 billion to sustain an antibiotic pipeline that is on the verge of collapse, a potentially devastating situation that could affect millions of people around the world,” Chairman and CEO of Eli Lilly and Company and President of IFPMA David Ricks said.
Read
Previous Coverage:
JUN 16, 2020 | RYAN W. STEVENS, PHARMD, BCIDP*
As the landscape of antimicrobial stewardship, both in the United States and globally, continues to change, programs will need to remain both curious and nimble to innovate and advance practice. Using the existing data within an institution to craft new and creative interventions across the continuum of care is sure to catalyze ongoing program­matic development.
The addition of vertical stewardship methods to preexisting horizontal methodologies represents one manner by which a program may further expand and/ or enhance its impact on patient outcomes, antimicrobial use, and health care costs.
Read
* - Author is an active member of the
